目的 探讨瘀血痹胶囊联合艾瑞昔布片治疗膝骨关节炎的临床疗效。方法 选取2020年3月—2022年3月中国人民解放军联勤保障部队第九〇四医院收治的130例膝骨关节炎患者，根据随机数字表法将所有患者分为对照组和治疗组，每组各65例。对照组餐后温水送服艾瑞昔布片，1片/次，2次/d。治疗组在对照组基础上口服瘀血痹胶囊，6粒/次，3次/d。两组患者连续用药8周。观察两组患者的临床疗效，采用视觉模拟评分法（VAS）评估两组患者的疼痛程度，采用改良版西安大略和麦克马斯特大学骨关节炎指数量表（WOMAC）评估两组患者的膝关节功能，比较两组患者治疗前后血清炎症因子白介素-1β（IL-1β）、白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、C反应蛋白（CRP）水平。结果 治疗后，治疗组总有效率（95.38%）高于对照组（84.62%），差异有统计学意义（P<0.05）。治疗后，两组VAS、WOMAC评分均显著下降（P<0.05），且治疗组VAS、WOMAC评分均明显低于对照组，差异有统计学意义（P<0.05）。治疗后，两组血清IL-1β、IL-6、TNF-α、CRP水平均显著下降（P<0.05），且治疗组血清IL-1β、IL-6、TNF-α、CRP水平低于对照组，差异具有统计学意义（P<0.05）。结论 瘀血痹胶囊联合艾瑞昔布片治疗膝骨关节炎具有较好的临床疗效，可有效缓解患者疼痛程度，改善膝关节功能，减轻炎症反应，且安全性较好。

Objective To investigate the clinical efficacy of Yuxuebi Capsules combined with Imrecoxib Tablets in treatment of knee osteoarthritis. Methods Patients (130 cases) with knee osteoarthritis in the 904th Hospital of the Joint Service Support Force of the Chinese People's Liberation Army from March 2020 to March 2022 were divided into control and treatment groups according to the random number table method, and each group had 65 cases. Patients in the control group were po administered with Imrecoxib Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Yuxuebi Capsules on the basis of the control group, 6 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and the VAS was used to evaluate the pain degree of two groups of patients, and the WOMAC was used to evaluate the knee joint function of two groups of patients. The serum levels of inflammatory factors (IL-1β, IL-6, TNF-α, and CRP) before and after treatment in two groups were compared. Results After treatment, the total effective rate of the treatment group (95.38%) was higher than that of the control group (84.62%), and the difference was statistically significant (P < 0.05). After treatment, the VAS scores and WOMAC scores of two groups were significantly decreased (P < 0.05), and the VAS score and WOMAC score of the treatment group were significantly lower than those of the control group, the difference was statistically significant (P < 0.05). After treatment, the serum levels of IL-1β, IL-6,TNF-α, and CRP in two groups were significantly decreased (P < 0.05), and the serum levels of IL-1β, IL-6, TNF-α, and CRP in the treatment group were lower than those in the control group, and the difference was statistically significant (P< 0.05). Conclusion Yuxuebi Capsules combined with Imrecoxib Tablets has clinical curative effect in treatment of knee osteoarthritis, which can effectively relieve pain, improve knee joint function, and reduce inflammation reaction, with good safety.

R982

太仓市科技计划项目（TC2020JCYL06）